Since in vitro assessment of exon skipping AOs targeting the ITGA4 transcript showed significant down-regulation of the ITGA4 transcript, protein and biological activity in both fibroblasts and Jurkat cells, we performed a proof-of-concept study in vivo using an EAE mouse model of MS. Here, ITGA4 is linked to myeloid sarcoma.